ATE388691T1 - Träger zur freisetzung von nanopartikeln - Google Patents

Träger zur freisetzung von nanopartikeln

Info

Publication number
ATE388691T1
ATE388691T1 AT02802543T AT02802543T ATE388691T1 AT E388691 T1 ATE388691 T1 AT E388691T1 AT 02802543 T AT02802543 T AT 02802543T AT 02802543 T AT02802543 T AT 02802543T AT E388691 T1 ATE388691 T1 AT E388691T1
Authority
AT
Austria
Prior art keywords
nanoparticle
delivery vehicle
active agent
nanoparticle delivery
target cell
Prior art date
Application number
AT02802543T
Other languages
English (en)
Inventor
Stefan Franzen
Daniel L Feldheim
Alexander G Tkachenko
Marisha L Godek
Joseph A Ryan
Miles F Anderson
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Application granted granted Critical
Publication of ATE388691T1 publication Critical patent/ATE388691T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
AT02802543T 2001-07-10 2002-07-10 Träger zur freisetzung von nanopartikeln ATE388691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30423601P 2001-07-10 2001-07-10

Publications (1)

Publication Number Publication Date
ATE388691T1 true ATE388691T1 (de) 2008-03-15

Family

ID=23175645

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02802543T ATE388691T1 (de) 2001-07-10 2002-07-10 Träger zur freisetzung von nanopartikeln

Country Status (9)

Country Link
US (2) US7332586B2 (de)
EP (2) EP1990040A1 (de)
JP (1) JP2005511761A (de)
AT (1) ATE388691T1 (de)
AU (1) AU2002364927A1 (de)
CA (1) CA2453417A1 (de)
DE (1) DE60225589T2 (de)
ES (1) ES2304467T3 (de)
WO (1) WO2003051278A2 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834349B2 (en) * 2000-03-29 2010-11-16 Georgia Tech Research Corporation Silicon based nanospheres and nanowires
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
WO2003075952A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
US7666410B2 (en) * 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
WO2004060378A2 (en) * 2002-12-20 2004-07-22 Kimberly-Clark Worldwide, Inc. Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof
US8282951B2 (en) 2003-01-13 2012-10-09 EnviroCare Corporation Antimicrobial coatings for treatment of surfaces in a building setting and method of applying same
US7641912B1 (en) * 2003-01-13 2010-01-05 EnviroCare Corporation Antimicrobial coatings for treatment of surfaces in a building setting and method of applying same
US7344887B2 (en) 2003-06-24 2008-03-18 Johns Hopkins University Methods and products for delivering biological molecules to cells using multicomponent nanostructures
US7682631B2 (en) * 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7438875B2 (en) 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US20070190155A1 (en) * 2004-03-05 2007-08-16 Leary James F Molecular programming of nanoparticle systems for an ordered and controlled sequence of events for gene-drug delivery
US7294340B2 (en) * 2004-03-30 2007-11-13 Chien-Min Sung Healthcare and cosmetic compositions containing nanodiamond
EP2330208B1 (de) 2004-05-24 2017-10-18 Midatech Ltd. Nanopartikel enthaltend RNA-Liganden
CA2573341A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for prevention of drug diversion
US20080118941A1 (en) * 2004-09-02 2008-05-22 The Regents Of The University Of California Signal Peptide-Semiconductor Nanocrystal Conjugates
US7935517B2 (en) * 2004-09-22 2011-05-03 Nanolab, Inc. Nanospearing for molecular transportation into cells
AU2005292083A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
AU2005291058B2 (en) * 2004-10-01 2011-09-29 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
GB0426182D0 (en) * 2004-11-30 2004-12-29 Univ St Andrews Photoporation of cells
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
WO2006084275A2 (en) 2005-02-04 2006-08-10 Auburn University Contact drug delivery system
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
US8388995B1 (en) 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
US8349352B2 (en) * 2005-02-04 2013-01-08 Auburn University Therapeutic contact lenses with anti-fungal delivery
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US20060246143A1 (en) * 2005-04-28 2006-11-02 Hilmi Ege Targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles
US20080206347A1 (en) * 2005-05-26 2008-08-28 Flamma S.P.A. Pharmaceutical Formulations Comprising Active Pharmaceutical Principles Adsorbed on Titanium Dioxide Nanoparticles
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
DE102005033855B4 (de) * 2005-07-12 2009-04-02 Siemens Ag Nanopartikel und Verfahren zum Transportieren eines Nanopartikels
WO2007014348A2 (en) * 2005-07-29 2007-02-01 North Carolina University Photocrosslinking probes and uses of the same
US9248034B2 (en) * 2005-08-23 2016-02-02 Advanced Cardiovascular Systems, Inc. Controlled disintegrating implantable medical devices
US8240190B2 (en) * 2005-08-23 2012-08-14 Uwm Research Foundation, Inc. Ambient-temperature gas sensor
US8268405B2 (en) * 2005-08-23 2012-09-18 Uwm Research Foundation, Inc. Controlled decoration of carbon nanotubes with aerosol nanoparticles
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
EP2021492A2 (de) * 2006-04-28 2009-02-11 Ludwig Institute For Cancer Research Quantifizierung von enzymaktivitäten durch massenspektrometrie
WO2008127414A2 (en) * 2006-11-08 2008-10-23 Northwestern University Colorimetric detection of metallic ions in aqueous media using functionlized nanoparticles
US20080138408A1 (en) * 2006-11-13 2008-06-12 Siddharth Venkatesh Drug delivery system and method
EP2099496A2 (de) * 2006-12-08 2009-09-16 Massachusetts Institute of Technology Freisetzung von nanopartikeln und/oder wirkstoffen in zellen
CA2691066C (en) * 2007-02-09 2018-07-31 Northwestern University Particles for detecting intracellular targets
EP2129803A4 (de) * 2007-02-27 2010-11-03 Univ Northwestern Anbringung von molekülen an nanopartikeln
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
AU2014262264B2 (en) * 2007-05-30 2017-01-05 Northwestern University Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications
DK2160464T3 (da) 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
US7807372B2 (en) * 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
EP2039254A1 (de) * 2007-09-14 2009-03-25 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Induzierbares Freigabemittel in Hybridform
WO2009038776A1 (en) * 2007-09-18 2009-03-26 Victor Manneh Therapeutic nanoconjugates
EP2205755A4 (de) 2007-10-17 2012-07-18 Cornell Res Foundation Inc System zur herstellung von adenosintriphosphat
US9186317B2 (en) * 2007-11-26 2015-11-17 Stc.Unm Active nanoparticles and method of using
WO2009131704A2 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
DE102008023228A1 (de) 2008-05-08 2009-11-19 Technische Universität Dresden Nanopartikel zur selektiven Gewebetherapie, Verfahren zu deren Herstellung und deren Verwendung in der Gewebetherapie
RU2444571C2 (ru) * 2008-05-28 2012-03-10 Учреждение Российской Академии наук Институт катализа им.Г.К.Борескова Сибирского отделения РАН (ИК СО РАН) Нанокомпозиты диоксида титана для инактивации вирусного генома внутри клеток, способ их получения
DE102008033175A1 (de) * 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
WO2010022321A1 (en) * 2008-08-21 2010-02-25 Georgia Tech Research Corporation Gas sensors, methods of preparation thereof, methods of selecting gas sensor materials, and methods of use of gas sensors
EP2349285B1 (de) 2008-10-10 2016-03-23 Dara Biosciences, Inc. Spicamycin-Derivat Enthaltend Nanoemulsionen zur Verwendundung in der Behandlung von Schmerzen
EP3335705A1 (de) 2008-11-24 2018-06-20 Northwestern University Polyvalente rna-nanopartikelzusammensetzungen
CA2749536A1 (en) * 2009-01-08 2010-07-15 Northwestern University Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) * 2009-01-15 2015-08-25 삼성전자주식회사 전자 사진용 토너 및 그의 제조방법
US20110033940A1 (en) * 2009-01-30 2011-02-10 Northwestern University Click chemistry, molecular transport junctions, and colorimetric detection of copper
AU2010237001B2 (en) 2009-04-15 2016-07-07 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9937128B2 (en) 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US20110073412A1 (en) 2009-09-28 2011-03-31 Tlt-Babcock, Inc. Axial fan compact bearing viscous pump
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
JP2012503494A (ja) * 2009-11-06 2012-02-09 チュン−アン ユニバーシティ インダストリー−アカデミー コーオペレイション ファンデイション ナノ粒子を含む遺伝子運搬体
US8445228B2 (en) * 2009-11-16 2013-05-21 Massachusetts Institute Of Technology Enhancement of in vitro translation by nanoparticle conjugates
CN102884204B (zh) * 2010-01-12 2015-03-25 新加坡科技研究局 利用纳米颗粒探针进行的核酸的序列选择性识别
EP2525780B1 (de) 2010-01-19 2022-09-07 Northwestern University Synthetische nanostrukturen mit nukleinsäuren und/oder anderen einheiten
EP2547328B1 (de) * 2010-02-11 2017-06-07 Ecole Polytechnique Federale de Lausanne (EPFL) Ccr7-liganden-verabreichung und co-verabreichung in einer immuntherapie
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
US9545421B2 (en) 2010-05-04 2017-01-17 General Electric Company Nucleic acid delivery vehicle and uses thereof
JP6343147B2 (ja) 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
WO2012061402A2 (en) * 2010-11-01 2012-05-10 Syracuse University System and method for delivery of dna-binding chemotherapy drugs using nanoparticles
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US9448231B2 (en) * 2011-02-28 2016-09-20 Ventana Medical Systems, Inc. Application of quantum dots for nuclear staining
US20120323112A1 (en) * 2011-06-17 2012-12-20 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles for accoustic imaging, methods of making, and methods of accoustic imaging
WO2013033802A1 (en) * 2011-09-08 2013-03-14 Nanox Tecnologia S/A Antimicrobial compositions and uses thereof
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
JP2014531898A (ja) 2011-09-11 2014-12-04 オーラセンス, エルエルシーAurasense, Llc 細胞取り込み制御システム
CA2847698C (en) 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
US9051583B2 (en) 2011-12-19 2015-06-09 Northwestern University Modified silica shell particles, and methods of making and using the same
GB201204579D0 (en) * 2012-03-15 2012-05-02 Univ Nottingham Trent Coating metal oxide particles
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
GB201209517D0 (en) * 2012-05-29 2012-07-11 Univ Birmingham Nanoparticles
US20140017263A1 (en) * 2012-06-28 2014-01-16 Clemson University Delivery Agents for Targeted Treatment of Elastin Degradation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2014185964A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
US9701985B2 (en) 2013-06-04 2017-07-11 Virginia Commonwealth University mda-9/syntenin promoter to image and treat metastatic cancer cells
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3024494A1 (de) 2013-07-25 2016-06-01 Exicure, Inc. Sphärische nukleinsäurebasierter konstrukte als immunregulatorische verbindungen
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US20160201031A1 (en) * 2013-08-21 2016-07-14 The Regents Of The University Of California Composition and methods for culturing cells
US10124045B2 (en) 2013-11-04 2018-11-13 Uti Limited Partnership Methods and compositions for sustained immunotherapy
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
WO2015070210A1 (en) 2013-11-11 2015-05-14 Wake Forest University Health Sciences Epha3 and multi-valent targeting of tumors
CN105939699B (zh) 2013-12-03 2020-10-02 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
CN104324380B (zh) * 2014-10-17 2017-08-01 华东理工大学 一种纳米药物载体及其制备方法和应用
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR20170104550A (ko) 2015-01-14 2017-09-15 엑시큐어, 인크. 코어 모티프를 갖는 핵산 나노구조
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
DE102016000865A1 (de) * 2016-01-28 2017-08-03 Friz Biochem Gesellschaft Für Bioanalytik Mbh Funktionalisierte metallische Nanopartikel
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CA3023451A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
ITUA20163432A1 (it) * 2016-05-13 2017-11-13 Fondazione St Italiano Tecnologia Processo per la preparazione di nanoparticelle cave con un core metallico
EP3463316A4 (de) * 2016-06-03 2020-05-27 Stemgenics, Inc. Funktionalisierte nanopartikel zur intrazellulären verabreichung von biologisch aktiven molekülen und verfahren zu deren herstellung und verwendung
US11845959B2 (en) 2016-06-16 2023-12-19 The Regents Of The University Of California Identification of factor that promotes human HSC self-renewal
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2018314159A1 (en) 2017-07-13 2020-01-30 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
WO2020089841A1 (en) 2018-10-31 2020-05-07 Garcia Joe G N Biomarkers and methods of use for radiation-induced lung injury
US20220175956A1 (en) 2019-03-06 2022-06-09 Northwestern University Hairpin-like oligonucleotide-conjugated spherical nucleic acid
CN111110855B (zh) * 2019-12-26 2023-06-23 深圳百纳心致生命科学有限公司 一种利用红细胞制备的靶向性的囊泡药物
EP4221685A1 (de) 2020-09-29 2023-08-09 Oxford University Innovation Limited Schlaganfallbehandlung
CN113209046B (zh) * 2021-05-08 2022-09-09 中国人民解放军陆军军医大学 一种CoSe@BSA纳米粒子药物组合物及其制备方法和应用
JP2024518793A (ja) * 2021-05-27 2024-05-02 アストラゼネカ・アクチエボラーグ 向上した安定性を有するｃａｓ９エフェクタータンパク質

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501726A (en) 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US5462751A (en) * 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
CA2151742C (en) 1993-02-22 1999-05-25 Alfred A. Amkraut Compositions for oral delivery of active agents
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
EP0706709A1 (de) 1993-06-30 1996-04-17 Carnegie Mellon University Metall, legierung, oder metallkarbid nanopartikeln und ihrer herstellungsverfahren
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739292B1 (fr) 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
AU7836598A (en) * 1997-06-13 1998-12-30 Johns Hopkins University, The Knobby nanospheres
US6106798A (en) 1997-07-21 2000-08-22 Nanogram Corporation Vanadium oxide nanoparticles
AU9570898A (en) 1997-09-18 1999-04-05 Gene Therapy Systems, Inc. Chemical modification of dna using peptide nucleic acid conjugates
DE60027030D1 (de) * 1999-09-27 2006-05-18 Elan Corp Membrantranslokierendes peptid als wirkstofftransportsystem
ATE520772T1 (de) * 2000-10-31 2011-09-15 Eisai Inc Nucleinsäure kodierend für cyp1b1 und methoden zur verwendung

Also Published As

Publication number Publication date
US7332586B2 (en) 2008-02-19
DE60225589D1 (de) 2008-04-24
US20080199529A1 (en) 2008-08-21
WO2003051278A2 (en) 2003-06-26
EP1450751A2 (de) 2004-09-01
EP1450751B1 (de) 2008-03-12
EP1990040A1 (de) 2008-11-12
AU2002364927A1 (en) 2003-06-30
JP2005511761A (ja) 2005-04-28
WO2003051278A3 (en) 2004-07-01
DE60225589T2 (de) 2009-04-23
EP1450751A4 (de) 2006-03-22
CA2453417A1 (en) 2003-06-26
ES2304467T3 (es) 2008-10-16
US20030147966A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
DE60225589D1 (de) Träger zur freisetzung von nanopartikeln
Wang et al. Advances and prospect of nanotechnology in stem cells
Zelikin et al. A general approach for DNA encapsulation in degradable polymer microcapsules
Gauriau et al. Posterior triangular thalamic neurons convey nociceptive messages to the secondary somatosensory and insular cortices in the rat
Sun et al. Intracellular tracking of single native molecules with electroporation-delivered quantum dots
BR9805335A (pt) Dispositivo e processo para fornecer um sinal, sistema de suspensão ativa de veículo e dispositivo para controlar a suspensão de um veículo.
DE60026544D1 (de) Verwendung von einfachen aminosäuren zur herstellung von porösen partikeln
CA2267973A1 (en) Hydrophilic microparticles and methods to prepare same
ES2138584T3 (es) Sistema de suministro de farmacos que implica la reaccion entre una proteina o un polipeptido y un polimero biodegradable hidrofobo.
ATE249209T1 (de) Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
CY1106387T1 (el) Τμηματοποιημενα μορια μεταφορεα αντιγονου (ματ-μορια) για τη διαμορφωση ανοσοαποκρισεων, αντιστοιχα δομηματα, μεθοδοι και χρησεις
Homaei et al. Immobilized papain on gold nanorods as heterogeneous biocatalysts
ATE161174T1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
Wong et al. Nanoceria as bona fide catalytic antioxidants in medicine: what we know and what we want to know…
DE60235234D1 (de) Hydrogelkugeln oder kapseln als künstliches medium zur eiablage von insekten und zucht von endoparasitoiden
Chen et al. Enhanced stability and bioconjugation of photo-cross-linked polystyrene-shell, Au-core nanoparticles
WO2003050260A3 (en) Streptavidin expressed gene fusions and methods of use thereof
Mayer-Kuckuk et al. Functional interaction of poly (ADP-ribose) with the 20S proteasome in vitro
Gao et al. Nanozymes: biomedical applications of enzymatic Fe 3 O 4 nanoparticles from in vitro to in vivo
Eustaquio et al. Nanobarcoding: detecting nanoparticles in biological samples using in situ polymerase chain reaction
Agarwal et al. Molecular motors as components of future medical devices and engineered materials
DE50303825D1 (de) Modifizierte oxidische nano-partikel mit hydrophoben einschlüssen, verfahren zu ihrer herstellung und verwendung dieser partikel
Hornyak Nanotechnology in otolaryngology
WO2001083754A3 (en) Cellular regulators of infectious agents and methods of use
Rathmann et al. Interaction, uptake, and processing of LbL‐coated microcarriers by PMNs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties